METHOD In this UK-based, multicentre study, 31 children with MOG antibody-associated relapsing disease were studied retrospectively.
INTERPRETATION MOG antibody should be tested in children presenting with relapsing neurological disorders associated with confluent, bilateral white matter changes, and distinct enhancement pattern. Children with MOG antibody-associated disease present with agerelated differences in phenotypes, with a severe leukoencephalopathy phenotype in the very young and normal intracranial MRI in the older children. This finding suggests a susceptibility of the very young and myelinating brain to MOG antibody-mediated mechanisms of damage.
There is growing evidence that a diagnosis of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease can be made in children with relapsing acquired demyelinating syndromes (ADS) whose sera are positive for MOG antibody. 1, 2 Previous studies have detected MOG antibody both at first presentation and at time of a relapse in children with ADS. [3] [4] [5] [6] In a recent, multicentre study, we detected MOG antibody in 83% of children with the phenotype of aquaporin-4 antibody-negative neuromyelitis optica spectrum disorder and 100% of patients originally diagnosed with multiphasic disseminated encephalomyelitis. 1 Children with MOG antibody-associated disease were, overall, young (median age 6y), mainly female, and mainly presented with either optic neuritis with visual disturbance or acute disseminated encephalomyelitis (ADEM) with encephalopathy, motor deficits, seizures, and cerebellar symptoms. 1 Clinical and imaging patterns of ADS may share features with some inherited conditions such as mitochondrial disorders, X-linked Charcot-Marie-Tooth, mucopolysaccharidoses, galactosaemia, and L-2-hydroxyglutaric aciduria. 7 These differential diagnoses are most frequently suspected in children presenting with ADEM, 8 and more so when the disease becomes more chronic with recurrent relapses and progressive disabilities. 8 Magnetic resonance imaging (MRI) is felt to distinguish between the leukodystrophies and the acquired leukoencephalopathies. In very young children with leukodystrophies, brain MRI typically shows confluent and bilateral, essentially symmetric, white matter abnormalities. 7 Although contrast enhancement may support an acquired condition this can also be found in genetically defined white matter disorders. 9 Conversely, children with ADEM usually show multifocal and asymmetric white matter abnormalities on MRI. 7 In our previous study, 1 we found that patients with MOG antibody-associated disease can share clinical and MRI similarities with leukodystrophies.
The aim of this study was to examine whether there were age-related differences in MOG antibody-associated disease phenotypes, with an emphasis on the 'leukodystrophy-like' pattern.
METHOD
In this retrospective study, we collected data from 31 participants attending three centres of the UK and Ireland Childhood CNS Inflammatory Demyelination Working Group: Great Ormond Street Hospital (London), Evelina London Children Hospital, and Birmingham Children Hospital; 26 cases have been included in a previous study and an additional five cases were studied.
1 All children had (1) a diagnosis of ADS, defined as two or more episodes of acquired central nervous system demyelinating events characterized by deficits persisting for at least 24 hours and involving the optic nerve, brain, or spinal cord, and associated with focal T2 abnormalities on brain and/or spinal cord MRI; (2) presence of MOG antibody detected either at onset or at the time of a clinical relapse, using live cell-based assays; 9 (3) (at onset) were younger than 18 years of age.
Demographic characteristics and clinical information on type of presentation, disability at onset (as measured by the Expanded Disability Status Scale [EDSS]), disease-modifying treatments, and number of relapses over time were collected. Outcomes at last follow-up were retrieved from the patients' medical records to represent the most contemporary assessment of disability (stratified to cognitive, motor, visual defects, and seizures). If unavailable, the information was obtained directly from the patient's primary treating physician. EDSS results were documented at point of disease stability at least 3 months from acute or relapsing events. The brain and spinal cord MRI of the 31 children were reviewed (FB) and the following three patterns (in order of frequency) were identified, as previously described: 1 (1) multifocal, hazy/poorly marginated lesions involving both the grey and white matter; (2) spinal cord and/or optic nerve involvement with normal intracranial appearance or nonspecific white matter lesions; (3) extensive and confluent white matter abnormalities, with a largely symmetric distribution, resembling a 'leukodystrophy-like' MRI pattern.
Statistical analysis was performed using commercially available software GraphPad Prism 6 (GraphPad, La Jolla, CA, USA). The differences in age between MOG antibody-positive children presenting with ADEM and those presenting with optic neuritis and/or transverse myelitis, and between children with abnormal MRI and those with normal MRI were tested using the Mann-Whitney U test. The difference in age between the three imaging patterns, was investigated using the Kruskal-Wallis test. The differences in clinical and MRI characteristics between children with 'leukodystrophy-like' phenotype and the remaining cases were explored using Fisher's exact test.
This study was approved by Great Ormond Street Hospital Research and Development Department (reference: 16NC10).
RESULTS
The clinical and radiological characteristics of patients with MOG antibody-associated disease, followed-up for a median of 4 years, are shown in Table I .
Fourteen children presented with ADEM; they were younger than the remainder, who presented with optic neuritis and/or transverse myelitis (mean age 4.1y SD 1.9 vs 8.5 [3.3] y; p<0.001). Similarly, children who had an abnormal brain MRI were younger than patients with normal brain MRI at onset (n=20; mean age 4.6y SD 2.8 vs 8.5y SD 3.0; p=0.001) and at follow-up (mean age 4.8y SD 2.6 vs 9.5y SD 2.7; p<0.001) (Fig. S1 , online supporting information). The most common MRI pattern at onset was What this paper adds
• Myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination manifest with an age-related phenotype.
• Children with MOG antibody and 'leukodystrophy-like' imaging patterns tend to have poor response to second-line immunotherapy.
that of multifocal, hazy/poorly marginated lesions involving both grey and white matter, and the least common pattern at onset was the 'leukodystrophy-like' MRI pattern (Table I) . Over the course of the disease, seven children developed a 'leukodystrophy-like' pattern on MRI. All patients had moderately active disease with a median annual relapse rate of 1, despite treatment with diseasemodifying drugs in 12 children. All patients with abnormal MRI at onset showed a significant (although not complete) resolution of lesions at follow-up. Nevertheless, despite low disability levels (measured by the EDSS) at follow-up (Table I) , one-third (n=10) had ongoing cognitive problems.
Age-related differences in phenotypes
When the association between age and imaging patterns was examined, a 'leukodystrophy-like' pattern was seen more frequently in the youngest patients (mean age at onset 3.7[1.3]y, range 1.8-6y), whereas an MRI pattern of multifocal, hazy/poorly marginated lesions, involving both grey and white matter was seen in the middle age group (5.2[1.9]y). Isolated spinal cord and/or optic nerve involvement (with normal and/or non-specific white matter lesions on MRI) was seen in the oldest group (9.8[2.8]y; p=0.001) (Fig. 1) .
'Leukodystrophy-like' phenotype
Examples of the clinical and radiological patterns of 'leukodystrophy-like' lesions in MOG antibody-positive children are shown in Figure 2 and Table II . A summary of the cases can be found in Appendix S1 (online supporting information) together with serial imaging of all patients (Fig. S2, online supporting information) .
All seven children with the 'leukodystrophy-like' lesions were given a diagnosis of ADEM at presentation. The patients presented with encephalopathy (n=7), ataxia (n=7), optic neuritis (n=5), and/or seizures (n=3) at presentation or relapse. The final diagnosis was ADEM for cases 1 to 6, and AQP4-Ab negative neuromyelitis optica spectrum disorder for case 7. All patients showed clinical improvement after acute treatment with steroids, but, overall, the outcome was poor. Four patients continued to relapse despite treatment with disease-modifying drugs.
When we compared the clinical characteristics of the patients with 'leukodystrophy-like' MRI pattern with the remainder of the patients with MOG antibody, we found that patients with this phenotype showed a worse overall outcome at follow-up than the other patients (median EDSS 3[range 1-5] vs median EDSS 0; p=0.001). However, there was no difference in the total number of relapses between the 'leukodystrophy-like' phenotype and the rest of the group.
DISCUSSION
MOG antibody disease is increasingly recognized, but the full range of clinical phenotypes is not yet clear. In this study we describe an unexpected phenotype, not easily distinguished from that of genetic or metabolic leukodystrophies, in seven paediatric patients under the age of 7 years. The children presented with relapsing neurological syndromes associated with a 'leukodystrophy-like' imaging pattern that emerged over time. These children showed a good response to treatment with steroids, but four continued to relapse on conventional multiple sclerosis treatments, and only showed a partial response to second-line immunotherapy with azathioprine and mycophenolate mofetil. Persistent cognitive and behavioural problems were seen in four and ongoing seizures in three of these children. In these patients, MRI findings of predominantly confluent, bilateral white matter changes raised the differential diagnosis of a leukodystrophy. Interestingly, the MRI abnormalities did not always correlate with the clinical state of the child. Furthermore, the highly contrast-enhancing lesions and the dramatic resolution on follow-up scans, early in the course of the disease, supported a diagnosis of a neuroinflammatory leukoencephalopathy. This study demonstrates that clinical and radiological heterogeneity in MOG antibody-associated phenotypes is age dependent, with the youngest children presenting preferentially with extensive brain involvement and older children (and adults) 10 predominantly with optic neuritis and normal intracranial imaging. This is consistent with the evidence for more profound and severe white matter abnormalities in the early-onset and severely affected patients with leukodystrophies, such as DARS2, 11 than patients with late-onset and mild leukodystrophies. 12 The finding of a 'leukodystrophy-like' phenotype in young children may reflect susceptibility of the myelinating brain to MOG antibody-mediated disease. In rat studies, expression of MOG occurred after the initiation of myelination, from postnatal day 1 onwards. 13 MOG was detected primarily at the extracellular surface of myelin sheaths and oligodendrocytes, and only at low levels in the lamellae of compacted myelin and the myelin/axon border zone. 13, 14 Whether expression of MOG on the lamella surface persists into adult life is unclear. It is plausible that the expression decreases as myelination proceeds and is much lower in older children. 15 In addition, the myelinating brain may be more susceptible to MOG antibody disease caused by MOG expression on uncompacted myelin, with resulting immune-mediated damage and axonal loss. 16 Such factors may contribute to qualitative and quantitative differences in the imaging findings in younger children with demyelination and the poorer outcome seen in this group. The reduced susceptibility in the fully myelinated adult brain is consistent with the overall benign phenotype in adult cases of MOG antibody-Positive neuromyelitis optica spectrum disorder. [17] [18] [19] In a cohort of 56 adults with MOG antibody, the clinical course was favourable, with good clinical outcomes and minimal residual disability. 20 Although only two out of seven patients with 'leukodystrophy-like' phenotype demonstrated these radiological features at onset it is possible that the MRI was not performed at nadir or that there is a lag between clinical and radiological features. Alternatively, progressive loss of tissue integrity over time, leading to increasing neuroaxonal injury, may explain the diffuse acquired white matter injury, the poor cognitive outcome seen in this group, and the reduced response to immunotherapy over time. As seen in patients with genetic white matter disorders, MOG antibody-positive patients with a 'leukodystrophy-like' MRI pattern showed a worse outcome at follow-up than older patients. The EDSS, which is used to assess disabilities in demyelinating conditions, is more heavily weighted towards motor disabilities than cognitive disabilities; this may explain the overall low scores seen in the cohort with MOG antibodyassociated disease in general. Cognitive problems were seen in half of the children with abnormal MRI and were not reported in children with normal brain MRI. This finding is in keeping with recent studies observing perturbation of white matter trajectories and reduced age-expected brain growth (driven via reduced white matter growth) in children after a single episode of ADS with brain lesions. 21, 22 Taken together, the physiological processes occurring during brain maturation (including increased axonal size with more efficient axonal transport, and myelin maturation and compaction) might explain the heterogeneity of MOG antibody phenotype, with a more severe leukoencephalopathy phenotype in the very young. Further studies into the exact pathobiological disease processes may result in better treatments and improved outcome in this distinct group of patients. and Toshiba Medical Systems; and has served on speakers' bureaus for Serono Symposia Foundation and MedScape. OC serves as a consultant for GE, Biogen Idec, and Novartis, and all the payments are made to the institution (Queen Square MS Centre, UCL Institute of Neurology, London, UK).
SUPPORTING INFORMATION
The following additional material may be found online: Figure S1 : Box plots showing the median and interquartile range. Figure S2 : Serial imaging at follow-up of the seven index cases using axial T2-weighted sequences.
Appendix S1: 'Leukodystrophy-like' phenotype -case summaries.
